Chirfi Guindo Sells 10,000 Shares of Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) CMO Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Chirfi Guindo also recently made the following trade(s):

• On Thursday, February 5th, Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00.

Merck & Co., Inc. Stock Down 3.5%

Shares of NYSE:MRK traded down $4.26 during trading on Monday, reaching $117.67. 16,007,310 shares of the company traded hands, compared to its average volume of 14,144,574. The firm has a fifty day simple moving average of $106.58 and a 200 day simple moving average of $93.29. The company has a quick ratio of 1.44, a current ratio of 1.66 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $122.66. The firm has a market cap of $292.06 billion, a P/E ratio of 16.16, a price-to-earnings-growth ratio of 2.28 and a beta of 0.28.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 45.22%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s payout ratio is 46.70%.

Wall Street Analyst Weigh In

MRK has been the subject of a number of research analyst reports. Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Cantor Fitzgerald upped their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a report on Thursday, January 8th. UBS Group lifted their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Morgan Stanley lifted their target price on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research report on Friday, December 12th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Hold” and an average target price of $119.53.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Chemung Canal Trust Co. lifted its stake in Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after purchasing an additional 13,285 shares during the last quarter. First Pacific Financial increased its position in Merck & Co., Inc. by 14.7% during the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after purchasing an additional 6,082 shares in the last quarter. Diversified Trust Co lifted its stake in Merck & Co., Inc. by 9.6% in the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after purchasing an additional 18,187 shares during the last quarter. Caxton Associates LLP boosted its position in Merck & Co., Inc. by 23.3% in the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after buying an additional 7,458 shares in the last quarter. Finally, Amplius Wealth Advisors LLC grew its stake in shares of Merck & Co., Inc. by 117.4% during the second quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock worth $488,000 after buying an additional 3,329 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda patent protection extended to late‑2029 and strategic execution could unlock near‑term cash and boost longer‑term value—analyst note calls MRK a “buy” for 2026 and forecasts material upside from QLEX migration and other levers. Merck: A Buy For 2026, But The Clock Is Still Ticking
• Positive Sentiment: Bull case argues the recent price surge isn’t excessive given a diverse portfolio, new approvals (QLEX), strong vaccine performance (Capvaxive up ~460%), and ongoing pipeline innovation to offset future Keytruda erosion. Merck: The Spike Doesn’t Make It Overvalued
• Positive Sentiment: Recent analyst upgrade has already supported an earlier price uptick, reflecting renewed investor enthusiasm around growth and dividend attractiveness. Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.8% After Analyst Upgrade
• Positive Sentiment: Investment write‑ups highlight Merck as a Dow Dividend candidate for long‑term income investors, reinforcing buy‑and‑hold demand for dividend strategies. 3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026
• Neutral Sentiment: Longer-form bull case pieces are circulating that recap upside scenarios and risks; useful for context but not a single catalytic item. Merck Co., Inc. (MRK): A bull case theory
• Negative Sentiment: Street sentiment cooled with a recent downgrade, which can pressure momentum investors and reduce near‑term upside. From Bargain To Balancing Act: Merck’s Next Test Begins (Rating Downgrade)
• Negative Sentiment: Several high‑profile insider sales (CFO, EVP and other executives) totaling multi‑million dollars were reported over the last 48 hours; large insider dispositions often raise short‑term concern about insider conviction. Merck & Co., Inc. (NYSE:MRK) CFO Sells $5,023,261.17 in Stock Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $4,556,870.20 in Stock Dean Li Sells 15,087 Shares of Merck & Co., Inc.
• Negative Sentiment: Another boutique outlet lowered its rating, adding to the mix of caution from some analysts and possibly amplifying volatility. Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Wall Street Zen

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.